Systematic Review of Tocilizumab for Rheumatoid Arthritis: A New Biologic Agent Targeting the Interl...
Systematic Review of Tocilizumab for Rheumatoid Arthritis: A New Biologic Agent Targeting the Interleukin-6 Receptor
About this item
Full title
Author / Creator
Publisher
Bridgewater, NJ: EM Inc USA
Journal title
Language
English
Formats
Publication information
Publisher
Bridgewater, NJ: EM Inc USA
Subjects
More information
Scope and Contents
Contents
AbstractBackgroundTocilizumab (TCZ), a humanized anti–interleukin-6 receptor monoclonal antibody, represents a new treatment strategy for patients with rheumatoid arthritis (RA) and is currently approved in the United States for RA patients who have failed to improve with at least one anti–tumor necrosis factor therapy. ObjectiveThe goal of this st...
Alternative Titles
Full title
Systematic Review of Tocilizumab for Rheumatoid Arthritis: A New Biologic Agent Targeting the Interleukin-6 Receptor
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1033160441
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1033160441
Other Identifiers
ISSN
0149-2918
E-ISSN
1879-114X
DOI
10.1016/j.clinthera.2012.02.014
